87 related articles for article (PubMed ID: 6677708)
21. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Uchijima Y; Saitoh H
Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620
[TBL] [Abstract][Full Text] [Related]
22. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
23. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
24. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
25. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer.
Røhl HF; Beuke HP
Scand J Urol Nephrol; 1992; 26(1):11-4. PubMed ID: 1631501
[TBL] [Abstract][Full Text] [Related]
26. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
27. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
28. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
Maleeva A; Tsvetkov M; Kekhaĭova M
Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
[TBL] [Abstract][Full Text] [Related]
29. Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer.
Egawa S; Okusa H; Matsumoto K; Suyama K; Baba S
Prostate Cancer Prostatic Dis; 2003; 6(3):245-9. PubMed ID: 12970730
[TBL] [Abstract][Full Text] [Related]
30. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
31. Hypogonadism in male patients with cancer.
Garcia JM; Li H; Mann D; Epner D; Hayes TG; Marcelli M; Cunningham GR
Cancer; 2006 Jun; 106(12):2583-91. PubMed ID: 16688773
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer. The Japan Flutamide Study Group.
Akaza H; Usami M; Kotake T; Koiso K; Aso Y
Jpn J Clin Oncol; 1993 Jun; 23(3):178-85. PubMed ID: 7688829
[TBL] [Abstract][Full Text] [Related]
33. Association between prostate cancer and serum testosterone levels.
Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
[TBL] [Abstract][Full Text] [Related]
34. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
36. Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Petrozziello A; Migliorini F; Caruso B; Cocco C; Sava T; Ghimenton C; Romano M; Monaco C; Comunale L
Anticancer Res; 2011 Mar; 31(3):1071-8. PubMed ID: 21498741
[TBL] [Abstract][Full Text] [Related]
37. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory.
Zumoff B; Levin J; Strain GW; Rosenfeld RS; O'Connor J; Freed SZ; Kream J; Whitmore WS; Fukushima DK; Hellman L
Prostate; 1982; 3(6):579-88. PubMed ID: 7155990
[TBL] [Abstract][Full Text] [Related]
38. Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels.
Imamoto T; Suzuki H; Utsumi T; Endo T; Takano M; Yano M; Kawamura K; Kamiya N; Nihei N; Naya Y; Ichikawa T
Future Oncol; 2009 Sep; 5(7):1005-13. PubMed ID: 19792969
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. British Prostate Study Group.
Br J Urol; 1979 Oct; 51(5):382-9. PubMed ID: 533596
[TBL] [Abstract][Full Text] [Related]
40. [Blood levels of testosterone and dihydrotestosterone in breast cancer].
Vitola GIa; Zeĭkate GA
Vopr Onkol; 1976; 22(8):26-30. PubMed ID: 997415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
